CDK inhibitor

Results: 20



#Item
1Microsoft PowerPoint - Figure 1 Final 1.ppt

Microsoft PowerPoint - Figure 1 Final 1.ppt

Add to Reading List

Source URL: canalbq.spb.pt

Language: English - Date: 2012-03-02 17:43:10
2Preliminary Programme Cell Cycle Regulators/Inhibitors and Cancer February 5-8, 2011, Vienna Austria Saturday, February – 18.00

Preliminary Programme Cell Cycle Regulators/Inhibitors and Cancer February 5-8, 2011, Vienna Austria Saturday, February – 18.00

Add to Reading List

Source URL: viscea.org

Language: English - Date: 2014-07-18 02:56:43
3DOI:.CANChromosomal Instability Confers Intrinsic Multidrug Resistance Alvin J.X. Lee, David Endesfelder, Andrew J. Rowan, et al. Cancer Res 2011;71:Published online March 1, 2011.

DOI:.CANChromosomal Instability Confers Intrinsic Multidrug Resistance Alvin J.X. Lee, David Endesfelder, Andrew J. Rowan, et al. Cancer Res 2011;71:Published online March 1, 2011.

Add to Reading List

Source URL: biolog.com

Language: English - Date: 2012-03-21 14:33:16
4The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit Sabrina L. Spencer1, Steven D. Cappell1, Feng-Chiao Tsai1, Tobias Meyer1  Tissue homeostasis in metazoans is regulated

The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit Sabrina L. Spencer1, Steven D. Cappell1, Feng-Chiao Tsai1, Tobias Meyer1 Tissue homeostasis in metazoans is regulated

Add to Reading List

Source URL: q-bio.org

Language: English - Date: 2013-07-16 19:10:08
5Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase

Mutations in the PCNA-binding site of CDKN1C inhibit cell proliferation by impairing the entry into S phase

Add to Reading List

Source URL: www.celldiv.com

Language: English
6Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,

Identification of a Predicted Biologically Effective Dose of AT7519, a Cyclin Dependent Kinase Inhibitor, in a Phase I Study[removed]M. S. Squires1, V. Lock1, J. Adam2 , D. Smith1, N. T. Thompson1, M. Yule1, J. F. Lyons1,

Add to Reading List

Source URL: astx.com

Language: English - Date: 2012-12-13 18:06:00
7AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C

AT7519, a Selective Small Molecule Inhibitor of Cyclin Dependent Kinases: Pharmacodynamic Biomarker Activity in a Phase I Study. Author(s) MS Squires, PJ Sweeney, V Lock, NT Thompson, D Smith, EJ Lewis, NJ Gallagher, H C

Add to Reading List

Source URL: astx.com

Language: English
8AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2.  INTRODUCTION

AT7519, a Potent Multi-targeted CDK Inhibitor, is Active in CLL Patient Samples Independent of Stage 3161 V Lock1, L Cooke2, M Yule1, NT Thompson1, K Della Croce2, JF Lyons1,MS Squires1,D Mahadevan2. INTRODUCTION

Add to Reading List

Source URL: astx.com

Language: English
9AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF

AT7519, A Potent CDK Inhibitor, is Active in Leukaemia Models and Primary CLL Patient Samples MS Squires1, RE Feltell1, V Lock1, D Smith1, EJ Lewis1, J Higgins1, M Yule1, NT Thompson1, L Cooke2, K Della Croce2, W Qi2, JF

Add to Reading List

Source URL: astx.com

Language: English
10A Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines. Author(s) MS Squires, R E Feltell, V Lock, D Smith, EJ Lewis, J Higgins, M Yule, D M Cross, NT Thompson, JF Lyons

A Comparison of the Pharmacological Profile of AT7519 in Solid Tumour and Haematological Cell Lines. Author(s) MS Squires, R E Feltell, V Lock, D Smith, EJ Lewis, J Higgins, M Yule, D M Cross, NT Thompson, JF Lyons

Add to Reading List

Source URL: astx.com

Language: English - Date: 2012-12-13 18:06:00